Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
After finishing at $14.38 in the prior trading day, Amicus Therapeutics Inc (NASDAQ: FOLD) closed at $14.31, down -0.49%. In other words, the price has decreased by -$0.49 from its previous closing price. On the day, 5.2 million shares were traded. FOLD stock price reached its highest trading level at $14.37 during the session, while it also had its lowest trading level at $14.305.
Ratios:
Our goal is to gain a better understanding of FOLD by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 16.78 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 456.78. For the most recent quarter (mrq), Quick Ratio is recorded 2.09 and its Current Ratio is at 2.99. In the meantime, Its Debt-to-Equity ratio is 1.92 whereas as Long-Term Debt/Eq ratio is at 1.88.
On December 22, 2025, TD Cowen Downgraded its rating to Hold which previously was Buy but kept the price unchanged to $14.50.
On December 17, 2025, Citigroup started tracking the stock assigning a Buy rating and target price of $17.Citigroup initiated its Buy rating on December 17, 2025, with a $17 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 19 ’25 when Clark David Michael sold 25,642 shares for $14.17 per share. The transaction valued at 363,380 led to the insider holds 245,690 shares of the business.
DAVID CLARK bought 25,642 shares of FOLD for $279,241 on Dec 19 ’25. On Dec 15 ’25, another insider, Campbell Bradley L, who serves as the President and CEO of the company, sold 77,926 shares for $10.86 each. As a result, the insider received 846,011 and left with 1,129,782 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, FOLD now has a Market Capitalization of 4426110976 and an Enterprise Value of 4594093056. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.39 while its Price-to-Book (P/B) ratio in mrq is 19.16. Its current Enterprise Value per Revenue stands at 7.673 whereas that against EBITDA is 109.072.
Stock Price History:
The Beta on a monthly basis for FOLD is 0.38, which has changed by 0.5281615 over the last 52 weeks, in comparison to a change of 0.15507638 over the same period for the S&P500. Over the past 52 weeks, FOLD has reached a high of $14.38, while it has fallen to a 52-week low of $5.51. The 50-Day Moving Average of the stock is 25.62%, while the 200-Day Moving Average is calculated to be 75.87%.
Shares Statistics:
The stock has traded on average 10.25M shares per day over the past 3-months and 13494440 shares per day over the last 10 days, according to various share statistics. A total of 308.50M shares are outstanding, with a floating share count of 303.22M. Insiders hold about 1.97% of the company’s shares, while institutions hold 101.94% stake in the company. Shares short for FOLD as of 1767139200 were 19056494 with a Short Ratio of 1.86, compared to 1764288000 on 19305562. Therefore, it implies a Short% of Shares Outstanding of 19056494 and a Short% of Float of 6.2.
Earnings Estimates
The firm’s stock currently is rated by 5.0 analysts. The consensus estimate for the next quarter is $0.09, with high estimates of $0.14 and low estimates of $0.04.
Analysts are recommending an EPS of between $0.44 and $0.32 for the fiscal current year, implying an average EPS of $0.38. EPS for the following year is $0.65, with 5.0 analysts recommending between $0.79 and $0.56.
Revenue Estimates
9 analysts predict $179.76M in revenue. The current quarter. It ranges from a high estimate of $184.74M to a low estimate of $174.31M. As of. The current estimate, Amicus Therapeutics Inc’s year-ago sales were $149.71MFor the next quarter, 9 analysts are estimating revenue of $161.59M. There is a high estimate of $172.6M for the next quarter, whereas the lowest estimate is $148.55M.
A total of 10 analysts have provided revenue estimates for FOLD’s current fiscal year. The highest revenue estimate was $635.5M, while the lowest revenue estimate was $623.3M, resulting in an average revenue estimate of $629.23M. In the same quarter a year ago, actual revenue was $528.29MBased on 10 analysts’ estimates, the company’s revenue will be $745.39M in the next fiscal year. The high estimate is $756.2M and the low estimate is $735.87M.
